These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30912053)

  • 1. Toward In Vivo Gene Therapy Using CRISPR.
    Skipper KA; Mikkelsen JG
    Methods Mol Biol; 2019; 1961():293-306. PubMed ID: 30912053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of CRISPR-Cas9-Mediated Genome Editing for the Treatment of Myotonic Dystrophy Type 1.
    Marsh S; Hanson B; Wood MJA; Varela MA; Roberts TC
    Mol Ther; 2020 Dec; 28(12):2527-2539. PubMed ID: 33171139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice.
    El Refaey M; Xu L; Gao Y; Canan BD; Adesanya TMA; Warner SC; Akagi K; Symer DE; Mohler PJ; Ma J; Janssen PML; Han R
    Circ Res; 2017 Sep; 121(8):923-929. PubMed ID: 28790199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postnatal Cardiac Gene Editing Using CRISPR/Cas9 With AAV9-Mediated Delivery of Short Guide RNAs Results in Mosaic Gene Disruption.
    Johansen AK; Molenaar B; Versteeg D; Leitoguinho AR; Demkes C; Spanjaard B; de Ruiter H; Akbari Moqadam F; Kooijman L; Zentilin L; Giacca M; van Rooij E
    Circ Res; 2017 Oct; 121(10):1168-1181. PubMed ID: 28851809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome Editing of Monogenic Neuromuscular Diseases: A Systematic Review.
    Long C; Amoasii L; Bassel-Duby R; Olson EN
    JAMA Neurol; 2016 Nov; 73(11):1349-1355. PubMed ID: 27668807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina.
    Yu W; Wu Z
    Methods Mol Biol; 2019; 1950():123-139. PubMed ID: 30783971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing.
    Min YL; Chemello F; Li H; Rodriguez-Caycedo C; Sanchez-Ortiz E; Mireault AA; McAnally JR; Shelton JM; Zhang Y; Bassel-Duby R; Olson EN
    Mol Ther; 2020 Sep; 28(9):2044-2055. PubMed ID: 32892813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral Delivery of Compact CRISPR-Cas12f for Gene Editing Applications.
    Sharrar A; Meacham Z; Staples-Ager J; Arake de Tacca L; Rabuka D; Collingwood T; Schelle M
    CRISPR J; 2024 Jun; 7(3):150-155. PubMed ID: 38695159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AAV-CRISPR Gene Editing Is Negated by Pre-existing Immunity to Cas9.
    Li A; Tanner MR; Lee CM; Hurley AE; De Giorgi M; Jarrett KE; Davis TH; Doerfler AM; Bao G; Beeton C; Lagor WR
    Mol Ther; 2020 Jun; 28(6):1432-1441. PubMed ID: 32348718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9 in genome editing: Its function and medical applications.
    Khadempar S; Familghadakchi S; Motlagh RA; Farahani N; Dashtiahangar M; Rezaei H; Gheibi Hayat SM
    J Cell Physiol; 2019 May; 234(5):5751-5761. PubMed ID: 30362544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.
    Yin C; Zhang T; Qu X; Zhang Y; Putatunda R; Xiao X; Li F; Xiao W; Zhao H; Dai S; Qin X; Mo X; Young WB; Khalili K; Hu W
    Mol Ther; 2017 May; 25(5):1168-1186. PubMed ID: 28366764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Genetic Disorders Using State-Of-The-Art Technology.
    Jamal M; Ullah A; Ahsan M; Tyagi R; Habib Z; Khan FA; Rehman K
    Curr Issues Mol Biol; 2018; 26():33-46. PubMed ID: 28879854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The gRNA Vector Level Determines the Outcome of Systemic AAV CRISPR Therapy for Duchenne Muscular Dystrophy.
    Wasala NB; Million ED; Watkins TB; Wasala LP; Han J; Yue Y; Lu B; Chen SJ; Hakim CH; Duan D
    Hum Gene Ther; 2022 May; 33(9-10):518-528. PubMed ID: 35350865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-gRNA Design.
    Pallarès Masmitjà M; Knödlseder N; Güell M
    Methods Mol Biol; 2019; 1961():3-11. PubMed ID: 30912036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 gene-editing strategies in cardiovascular cells.
    Vermersch E; Jouve C; Hulot JS
    Cardiovasc Res; 2020 Apr; 116(5):894-907. PubMed ID: 31584620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9 DNA Base-Editing and Prime-Editing.
    Kantor A; McClements ME; MacLaren RE
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR: development of a technology and its applications.
    Derry WB
    FEBS J; 2021 Jan; 288(2):358-359. PubMed ID: 33300275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and Simple Screening of CRISPR Guide RNAs (gRNAs) in Cultured Cells Using Adeno-Associated Viral (AAV) Vectors.
    Fakhiri J; Nickl M; Grimm D
    Methods Mol Biol; 2019; 1961():111-126. PubMed ID: 30912043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.